India, May 20 -- Tourmaline Bio, Inc. (TRML), Tuesday reported positive topline results from its Phase 2 TRANQUILITY study evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein (hs-CRP), and chronic kidney disease (CKD).
In the study, participants were randomized to receive pacibekitug 25 mg quarterly, 50 mg quarterly, or 15 mg monthly, or placebo, for a period of 6 months. Participants are then followed for an additional 6 months. Topline data from the study showed rapid, deep, and durable reductions in hs-CRP through Day 90. Patients who received pacibekitug 50 mg quarterly achieved more than 85% reductions in hs-CRP from baseline.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843...